Acute Lymphoblastic Leukemia

The inherited GATA3 variant rs3824662 was found to strongly influence response to remission induction therapy in childhood acute lymphoblastic leukemia and was also associated with relapse.

Researchers suggested that a scoring system may aid in determining the appropriate use of HSCT in this patient population.

According to researchers, this “group represents more than 20% of children and young adults with ALL, and an increase in attention to adherence, supportive care, and logistics for patients living [more than 50] miles from their treatment center is warranted.”